个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Zhou, C.[1] * ; Wang, Z.[2] ; Sun, M.[3] ; Cao, L.[4] ; Ma, Z.[5] ; Wu, R.[6] ; Yu, Y.[7] ; Yao, W.[8] ; Sun, S.[9] ; Chen, J.[10] ; Zhuang, W.[11] ; Cui, J.[12] ; Chen, X.[13] ; Lu, Y.[14] ; Hu, C.[15] ; Wang, J.[16] ; Wang, Q.[16] ; Wang, B.[16] ; Dai, H.[16] ; Yang, J. J.[16] ;
机构： [1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China [3]Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China [4]Department of Respiratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, China [5]Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China [6]Department of Oncology, Shengjing Hospital of China Medical University, Huaxiang Branch Hospital, Shenyang, Liaoning, China [7]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China [8]Thoracic Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, China [9]Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [10]Department of Thoracic Oncology, Hunan Cancer Hospital, Changsha, China [11]Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China [12]Department of Oncology, The First Hospital of Jilin University, Changchun, China [13]Department of Thoracic Oncology, The Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Zhejiang University Cancer Centre, Hangzhou, China [14]Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [15]Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China [16]Clinical Development, CStone Pharmaceuticals Co., Ltd., Shanghai, China
出处：
DOI： 10.1016/j.annonc.2024.08.1374
ISSN：
基金：
CStone Pharmaceuticals
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
推荐引用方式(GB/T 7714)：
Zhou C.,Wang Z.,Sun M.,et al.Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)[J].ANNALS OF ONCOLOGY.2024,35:S839-S839.doi:10.1016/j.annonc.2024.08.1374.
APA：
Zhou, C.,Wang, Z.,Sun, M.,Cao, L.,Ma, Z....&Yang, J. J..(2024).Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC).ANNALS OF ONCOLOGY,35,
MLA：
Zhou, C.,et al."Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)".ANNALS OF ONCOLOGY 35.(2024):S839-S839

资源点击量：57699 今日访问量：0 总访问量：4768 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号